孟思博 趙成

摘 ? 要:目的 ?分析骨巨細(xì)胞瘤的治療方案與并發(fā)癥的相關(guān)性。方法 ?回顧性分析2005年1月~2013年12月于山東大學(xué)齊魯醫(yī)院進(jìn)行骨巨細(xì)胞瘤手術(shù)治療患者56例,記錄患者年齡、性別、腫瘤發(fā)生部位、術(shù)后輔助治療方案、術(shù)式及并發(fā)癥發(fā)生率。結(jié)果 ?術(shù)后進(jìn)行輔助治療患者并發(fā)癥發(fā)生率為43.48%,高于未進(jìn)行輔助治療患者的15.15%,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);采用腫瘤切除+物理化學(xué)方法治療患者并發(fā)癥發(fā)生率為41.94%,高于單純切除患者的0,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);擴(kuò)大切除組患者的并發(fā)癥發(fā)生率為12.50%,低于單純切除患者,高于切除+物理化學(xué)方法,差異均有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 ?骨巨細(xì)胞瘤患者術(shù)后放療或應(yīng)用雙膦酸鹽類藥物輔助治療,采用腫瘤切除+物理化學(xué)方法及腫瘤擴(kuò)大切除會(huì)增加患者術(shù)后并發(fā)癥的發(fā)生率,因此應(yīng)根據(jù)患者具體情況選擇術(shù)式。
關(guān)鍵詞:骨巨細(xì)胞瘤;并發(fā)癥;相關(guān)因素
中圖分類號(hào):R738.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 文獻(xiàn)標(biāo)識(shí)碼:A ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? DOI:10.3969/j.issn.1006-1959.2018.24.051
文章編號(hào):1006-1959(2018)24-0167-03
Abstract:Objective ?To analyze the the correlation between treatment regimen and complications of complications of giant cell tumor of bone. Methods ?A retrospective analysis of 56 patients with giant cell tumor of the bone at Qilu Hospital of Shandong University from January 2005 to December 2013 was performed. The age, sex, tumor location, postoperative adjuvant treatment, surgery and complications were recorded. Incidence. Results ?The incidence of postoperative complication was 43.48%, which was higher than that of 15.15% of patients without adjuvant therapy. The difference was statistically significant (P<0.05).The incidence of complication was 41.94% in patients treated with tumor resection+physical chemistry, which was significantly higher than that in patients with simple resection (P<0.05). The complication rate in patients with enlarged resection was 12.50%, low. In patients with simple resection, the difference was statistically significant (P<0.05). Conclusion ?In patients with giant cell tumor of the bone, postoperative radiotherapy or bisphosphonate adjuvant therapy, tumor resection + physicochemical methods and enlarged tumor resection will increase the incidence of postoperative complications, so the choice should be based on the patient's specific conditions.
Key words:Giant cell tumor of bone;Complications;Related factors
骨巨細(xì)胞瘤(giant cell tumor of bone,GCTB)是發(fā)病率較高的一種具有惡性傾向的骨腫瘤,1818 年由 Copper首次描述,占所有原發(fā)性骨腫瘤的3%~5%,良性骨腫瘤的15%[1]。骨巨細(xì)胞瘤發(fā)病年齡在20~50歲,四肢長骨干骺端最為常見,尤其是臨近膝關(guān)節(jié)的股骨遠(yuǎn)端和脛骨近端,亦可發(fā)生于脊柱、骨盆等部位[2,3]。常規(guī)刮除術(shù)后有較高的局部復(fù)發(fā)率,肺轉(zhuǎn)移率1%~9%[4,5]。骨巨細(xì)胞瘤生物學(xué)行為復(fù)雜多變,呈侵襲性生長,并且具有局部復(fù)發(fā)傾向,部分患者發(fā)生肺轉(zhuǎn)移或肉瘤變,預(yù)后極差[6,7]。一直以來,骨巨細(xì)胞瘤的研究從細(xì)胞發(fā)生、組織學(xué)性質(zhì)和分級(jí)方法等隨著科技社會(huì)的進(jìn)步而不斷發(fā)生變化[8,9]。手術(shù)治療為診斷時(shí)無遠(yuǎn)處轉(zhuǎn)移的骨巨細(xì)胞瘤患者的首選治療方案,只要患者能夠耐受手術(shù),均應(yīng)向其建議手術(shù)干預(yù)腫瘤的自然病程[10]。對(duì)于可切除的骨巨細(xì)胞瘤,主要的手術(shù)方式包括廣泛切除和病灶內(nèi)刮除兩種。雖然可以輔助放療、IFN、Denosumab等治療,但廣泛切除的復(fù)發(fā)率為0~12%,而刮除術(shù)的復(fù)發(fā)率為12%~65%,廣泛切除的復(fù)發(fā)風(fēng)險(xiǎn)較低,但大面積的手術(shù)切除會(huì)導(dǎo)致嚴(yán)重的并發(fā)癥或功能缺失,因此最理想的治療方案仍然沒有達(dá)成共識(shí)。……